| Potent, irreversible EGFR TKI of certain mutant EGFR forms [L858R, exon 19 deletion (ex19del), and T790M], with minimal activity against wild type EGFR |
| Prolongs PFS relative to erlotinib or gefitinib in patients with advanced NSCLC, including those with CNS metastases, and irrespective of the EGFR mutation status (L858R or ex19del) |
| At the time of data cutoff, overall survival data not yet mature |
| Generally manageable tolerability profile, with most adverse events being of mild to moderate intensity |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.